Animal models of osteoporosis

Orthopaedic Issues in Osteoporosis

Volumn , Issue , 2002, Pages 71-89

  Hayashi, Kazuo ^a   Fotovati, Abbas ^a,b  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057441391     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (154)

1. Food and Drug Administration (FDA), Guidelines for Pre-clinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis, FDA Division of Metabolism and Endocrine Drug Products, Washington, D.C., 1994.
2. Kirkwood, T.B.L., “Comparative and evolutionary aspects of longevity,” in Handbook of the Biology of Aging, Finch, C.E. and Schneider, E.L., Eds., John Wiley & Sons, New York, 1985, 27.
3. Bellino, F.L., “Nonprimate animal models of menopause: workshop report,” Menopause, 7, 14, 2000.
4. Morrow, D.A., Current Therapy in Theriogenology, 2nd ed., W.B. Saunders, Philadelphia, 1986.
5. Kalu, D.N. and Chen, C., “Ovariectomized murine model of postmenopausal calcium malabsorption,” J. Bone Miner. Res., 14, 593, 1999.
6. Kitazawa, R., Kimble, R.B., Vannice, J.L., et al., “Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice,” J. Clin. Invest., 94, 2397, 1994.
7. Kimble, R.B., Bain, S., and Pacifici, R., “The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice,” J. Bone Miner. Res., 12, 935, 1997.
8. Okada, Y., Morimoto, I., Ura, K., et al., “Short-term treatment of recombinant murine interleukin-4 rapidly inhibits bone formation in normal and ovariectomized mice,” Bone, 22, 361, 1998.
9. Sandstedt, J., Tornell, J., Norjavaara, E., et al., “Elevated levels of growth hormone increase bone mineral content in normal young mice, but not in ovariectomized mice,” Endocrinology, 137, 3368, 1996.
10. Bhattacharyya, M.H., Whelton, B.D., Stern, P.H., et al., “Cadmium accelerates bone loss in ovariectomized mice and fetal rat limb bones in culture,” Proc. Natl. Acad. Sci. U.S.A., 85, 8761, 1988.
11. Alexander, J.M., Bab, I., and Fish, S., “Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice,” J. Bone Miner. Res., 16, 1665, 2001.
12. Bain, S.D., Bailey, M.C., Celino, D.L., et al., “High-dose estrogen inhibits bone resorption and stimulates bone formation in the ovariectomized mouse,” J. Bone Miner. Res., 8, 435, 1993.
13. Yamamoto, M., Fisher, J.E., and Gentile, M., “The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats,” Endocrinology, 139, 1411, 1998.
14. Andersson, N., Lindberg, M.K., and Ohlsson, C., “Repeated in vivo determinations of bone mineral density during parathyroid hormone treatment in ovariectomized mice,” J. Endocrinol., 170, 529, 2001.
15. Fujita, T., Kawata, T., Tokimasa, C., et al., “Breadth of the mandibular condyle affected by disturbances of the sex hormones in ovariectomized and orchiectomized mice,” Clin. Orthod. Res., 4, 172, 2001.
16. Miller, S.C., Bowman, B.M., and Jee, W.S., “Available animal models of osteopenia - small and large,” Bone, 17, 117S, 1995.
17. Kalu, D.N., “The ovariectomized rat model of postmenopausal bone loss,” Bone Miner., 15, 175, 1991.
18. Thompson, D.D., Simmons, H.A., Pirie, C.M., and Ke, H.Z., “FDA guidelines and animal models for osteoporosis,” Bone, 17, 125S, 1995.
19. Kinney, J.H., Haupt, D.L., Balooch, M., et al., “Three-dimensional morphometry of the L6 vertebra in the ovariectomized rat model of osteoporosis: biomechanical implications,” J. Bone Miner. Res., 15, 1981, 2000.
20. Elovic, R.P., Hipp, J.A., and Hayes, W.C., “Ovariectomy decreases the bone area fraction of the rat mandible,” Calcif. Tissue Int., 56, 305, 1995.
21. Morris, H.A., O’Loughlin, P.D., Mason, R.A., and Schulz, S.R., “The effects of oophorectomy on calcium homeostasis,” Bone, 17, 169S, 1995.
22. Francis, R.M., “Oral bisphosphonates in the treatment of osteoporosis: a review,” Curr. Ther. Res. Clin. Exp., 56, 831, 1995.
23. Civitelli, R., Gonnelli, S., Zacchei, F., et al., “Bone turnover in postmenopausal osteoporosis - effect of calcitonin treatment, " J. Clin. Invest., 82, 1268, 1988.
24. Turner, R.T., Riggs, B.L., and Spelsberg, T.C., “Skeletal effects of estrogen,” Endocr. Rev., 15, 275, 1994.
25. Mitlak, B.H. and Cohen, F.J., “In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators,” Horm. Res., 48, 155, 1997.
26. Miller, S.C., Hunziker, J., Mecham, M., and Wronski, T.J., “Intermittent parathyroid hormone administration stimulates bone formation in the mandibles of aged ovariectomized rats,” J. Dent. Res., 76, 1471, 1997.
27. Lindsay, R., Nieves, J., Henneman, E., et al., “Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone (1-34): kinetics and biochemical response in estrogenized osteoporotic patients,” J. Clin. Endocrinol. Metab., 77, 1535, 1993.
28. Ericksen, E.F., Mosekilde, L., and Melsen, F., “Effects of sodium fluoride, calcium phosphonate, and vitamin D2 on bone balance and remodeling in osteoporosis,” Bone, 6, 381, 1985.
29. Rohanizadeh, R., LeGeros, R.Z., Bohic, S., et al., “Ultrastructural properties of bone mineral of control and tiludronate-treated osteoporotic rat,” Calcif. Tissue Int., 67, 330, 2000.
30. Mochizuki, K. and Inoue, T., “Effect of salmon calcitonin on experimental osteoporosis induced by ovariectomy and low-calcium diet in the rat,” J. Bone Miner. Metab., 18, 194, 2000.
31. Kostenuik, P.J., Capparelli, C., Morony, S., et al., “OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats,” Endocrinology, 142, 4295, 2001.
32. Mosekilde, L., Tornvig, L., Thomsen, J.S., et al., “Parathyroid hormone and growth hormone have additive or synergetic effect when used as intervention treatment in ovariectomized rats with established osteopenia,” Bone, 26, 643, 2000.
33. Stewart, A.F., Cain, R.L., Burr, D.B., et al., “Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormonerelated protein 1-36, and SDZ-parathyroid hormone 893,” J. Bone Miner. Res., 15, 1517, 2000.
34. Ma, Y.F., Li, X.J., Jee, W.S.S., and McOsker, J., “Effects of prostaglandin E2 and F2 on the skeleton of osteopenic ovariectomized rats,” Bone, 17, 549, 1995.
35. Ke, H.Z., Shen, V.W., and Qi, H., “Prostaglandin E2 increases bone strength in intact rats and ovariectomized rats with established osteoporosis,” Bone, 23, 249, 1998.
36. Soper, D.L., Milbank, J.B., Mieling, G.E., et al., “Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis,” J. Med. Chem., 44, 4157, 2001.
37. Erben, R.G., Weiser, H., Sinowatz, F., et al., “Vitamin D metabolites prevent vertebral osteopenia in ovariectomized rats,” Calcif. Tissue Int., 50, 228, 1992.
38. Sakai, R. and Eto, Y., “Involvement of activin in the regulation of bone metabolism,” Mol. Cell Endocrinol., 180, 183, 2001.
39. Horcajada-Molteni, M.N., Davicco, M.J., Lebecque, P., et al., “Amylin inhibits ovariectomy-induced bone loss in rats,” J. Endocrinol., 165, 663, 2000.
40. Hayashi, K., Uenoyama, K., Matsuguchi, N., et al., “The affinity of bone to hydroxyapatite and alumina in experimentally induced osteoporosis,” J. Arthroplasty, 4, 257, 1989.
41. Hayashi, K., Uenoyama, K., Mashima, T., and Sugioka, Y., “Remodeling of bone around hydroxyapatite and titanium in experimental osteoporosis,” Biomaterials, 15, 11, 1994.
42. Hara, T., Hayashi, K., Nakashima, Y., et al., “The effect of hydroxyapatite coating on the bonding of bone to titanium implants in the femora of ovariectomised rats,” J. Bone Joint Surg. Br., 81, 705, 1999.
43. Gasser, J.A., “Assessing bone quantity by pQCT,” Bone, 17, 145S, 1995.
44. Ishihara, A., Sasaki, T., and Debari, K., “Effects of ovariectomy on bone morphology in maxillae of mature rats,” J. Electron. Microsc. (Tokyo), 48, 465, 1999.
45. Moriya, Y., Ito, K., and Murai, S., “Effects of experimental osteoporosis on alveolar bone loss in rats,” J. Oral Sci., 40, 171, 1998.
46. Hunziker, J., Wronski, T.J., and Miller, S.C., “Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone,” J. Dent. Res., 79, 1431, 2000.
47. Straub, B., Muller, M., Schrader, M., et al., “Osteoporosis and mild metabolic acidosis in the rat after orchiectomy and their prevention: should prophylactic therapy be administered to patients with androgen deprivation?" J. Urol., 165, 1783, 2001.
48. Lugero, G.G., de Falco Caparbo, V., Guzzo, M.L., et al., “Histomorphometric evaluation of titanium implants in osteoporotic rabbit,” Implant. Dent., 9, 303, 2000.
49. Hansen, V.B., Forman, A., Lundgaard, A., et al., “Effects of oophorectomy on functional properties of resistance arteries isolated from the cancellous bone of the rabbit femur,” J. Orthop. Res., 19, 391, 2001.
50. Dannucci, G.A., Martin, R.B., and Patterson-Buckendahl, P., “Ovariectomy and trabecular bone remodeling in the dog,” Calcif. Tissue Int., 40, 194, 1987.
51. Malluche, H.H., Faugere, M.C., Friedler, R.M., and Fanti, P., "1,25-Dihydroxyvitamin D3 corrects bone loss but suppresses bone remodeling in ovariohysterectomized beagle dogs,” Endocrinology, 122, 1998, 1988.
52. Faugere, M.C., Friedler, R.M., Fanti, P., and Malluche, H.H., “Bone changes occurring early after cessation of ovarian function in beagle dogs: a histomorphometric study employing sequential biopsies,” J. Bone Miner. Res., 5, 263, 1990.
53. Shen, V., Dempster, D.W., Birchman, R., et al., “Lack of changes in histomorphometric, bone mass, and biochemical parameters in ovariohysterectomized dogs,” Bone, 13, 311, 1992.
54. Fukuda, S. and Iida, H., “Effects of orchidectomy on bone metabolism in beagle dogs,” J. Vet. Med. Sci., 62, 69, 2000.
55. Newman, E., Turner, A.S., and Wark, J.D., “The potential of sheep for the study of osteopenia: current status and comparison with other animal models,” Bone, 16, 277S, 1995.
56. Scholz-Ahrens, K.E., Delling, G., Jungblut, P.W., et al., “Effect of ovariectomy on bone histology and plasma parameters of bone metabolism in nulliparous and multiparous sows,” Z. Ernaehrungswiss., 35, 13, 1996.
57. Mosekilde, L., Weisbrode, S.E., Safron, J.A., et al., “Calcium-restricted ovariectomized Sinclair S-1 minipigs: an animal model of osteopenia and trabecular plate perforation,” Bone, 14, 379, 1993.
58. Lill, C.A., Fluegel, A.K., and Schneider, E., “Sheep model for fracture treatment in osteoporotic bone: a pilot study about different induction regimens,” J. Orthop. Trauma, 14, 565, 2000.
59. Hornby, S.B., Ford, S.L., Mase, C.A., and Evans, G.P., “Skeletal changes in the ovariectomized ewe and subsequent response to treatment with 17 oestradiol,” Bone, 17, 389S, 1995.
60. Torricelli, P., Fini, M., Giavaresi, G., et al., “Isolation and characterization of osteoblast cultures from normal and osteopenic sheep for biomaterials evaluation,” J. Biomed. Mater. Res., 52, 177, 2000.
61. Thorndike, E.A. and Turner, A.S., “In search of an animal model for postmenopausal diseases,” Front. Biosci., 16, 17, 1998.
62. Johnson, R.B., Gilbert, J.A., Cooper, R.C., et al., “Alveolar bone loss one year following ovariectomy in sheep,” J. Periodontol., 68, 864, 1997.
63. Jerome, C.P. and Peterson, P.E., “Nonhuman primate models in skeletal research,” Bone, 29, 1, 2001.
64. Hotchkiss, C.E. and Brommage, R., “Changes in bone turnover during the menstrual cycle in cynomolgus monkeys,” Calcif. Tissue Int., 66, 224, 2000.
65. Colman, R.J., Kemnitz, J.W., Lane, M.A., et al., “Skeletal effects of aging and menopausal status in female rhesus macaques,” J. Clin. Endocrinol. Metab., 84, 4144, 1999.
66. Chen, Y., Shimizu, M., Sato, K., et al., “Effects of aging on bone mineral content and bone biomarkers in female cynomolgus monkeys,” Exp. Anim., 49, 163, 2000.
67. Jerome, C.P., Turner, C.H., and Lees, C.J., “Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis),” Calcif. Tissue Int., 60, 265, 1997.
68. Adams, M.R., Williams, J.K., Clarkson, T.B., et al., “Effects of oestrogens and progestogens on coronary atherosclerosis and osteoporosis of monkeys,” Baillieres Clin. Obstet. Gynaecol., 5, 915, 1991.
69. Mann, D.R., Gould, K.G., and Collins, D.C., “A potential primate model for bone loss resulting from medical oophorectomy or menopause,” J. Clin. Endocrinol. Metabol., 71, 105, 1990.
70. Mann, D.R., Rudman, C.G., Akinbami, M.A., and Gould, K.G., “Preservation of bone mass in hypogonadal female monkeys with recombinant human growth hormone administration,” J. Clin. Endocrinol. Metabol., 74, 1263, 1992.
71. Stroup, G.B., Hoffman, S.J., Vasko-Moser, J.A., et al., “Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: a short-term model for evaluation of antiresorptive therapy,” Bone, 28, 532, 2001.
72. Kapadia, R.D., Stroup, G.B., Badger, A.M., et al., “Applications of micro-CT and MR microscopy to study pre-clinical models of osteoporosis and osteoarthritis,” Technol. Health Care, 6, 361, 1998.
73. Mackey, M.S., Stevens, M.L., Ebert, D.C., et al., “The ferret as a small animal model with BMUbased remodeling for skeletal research,” Bone, 17, 191S, 1995.
74. Patschan, D., Loddenkemper, K., and Buttgereit, F., “Molecular mechanisms of glucocorticoid-induced osteoporosis,” Bone, 29, 498, 2001.
75. Weinstein, R.S., Jilka, R.L., Parfitt, A.M., and Manolagas, S.C., “Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone,” J. Clin. Invest., 15, 274, 1998.
76. Ortoft, G., Andreassen, T.T., and Oxlund, H., “Growth hormone increases cortical and cancellous bone mass in young growing rats with glucocorticoid-induced osteopenia,” J. Bone Miner. Res., 14, 710, 1999.
77. Cvetkovic, M., Mann, G.N., Romero, D.F., et al., “The deleterious effects of long-term cyclosporin A, cyclosporin C, and FK506 on bone mineral metabolism in vivo,” Transplantation, 57, 1231, 1994.
78. Grardel, B., Sutter, B., Flautre, B., et al., “Effects of glucocorticoids on skeletal growth in rabbits evaluated by dual-photon absorptiometry, microscopic connectivity and vertebral compressive strength,” Osteoporos. Int., 4, 204, 1994.
79. Waters, R.V., Gamradt, S.C., Asnis, P., et al., “Systemic corticosteroids inhibit bone healing in a rabbit ulnar osteotomy model,” Acta Orthop. Scand., 71, 316, 2000.
80. Fisher, D.E., “The role of fat embolism in the etiology of corticosteroid-induced avascular necrosis: clinical and experimental results,” Clin. Orthop., 130, 68, 1978.
81. Warman, M. and Boskey, A.L., “Effect of high levels of corticosteroids on the lipids of the long bones of the mature rabbit,” Metab. Bone Dis. Relat. Res., 4, 319, 1983.
82. Wang, G.J., Chung, K.C., and Shen, W.J., “Lipid clearing agents in steroid-induced osteoporosis,” J. Formos. Med. Assoc., 94, 589, 1995.
83. Southard, T.E., Southard, K.A., Krizan, K.E., et al., “Mandibular bone density and fractal dimension in rabbits with induced osteoporosis,” Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 89, 244, 2000.
84. Fujimoto, T., Niimi, A., Sawai, T., and Ueda, M., “Effects of steroid-induced osteoporosis on osseointegration of titanium implants,” Int. J. Oral Maxillofac. Implants, 13, 183, 1998.
85. Akkas, N., Yeni, Y.N., Turan, B., et al., “Effect of medication on biomechanical properties of rabbit bones: heparin induced osteoporosis,” Clin. Rheumatol., 16, 585, 1997.
86. Lyles, K.W., Jackson, T.W., Nesbitt, T., and Quarles, L.D., “Salmon calcitonin reduces vertebral bone loss in glucocorticoid-treated beagles,” Am. J. Physiol., 264, E938, 1993.
87. Chavassieux, P., Pastoureau, P., Chapuy, M.C., et al., “Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study,” Osteoporos. Int., 3, 97, 1993.
88. Takata, S. and Yasui, N., “Disuse osteoporosis,” J. Med. Invest., 48, 147, 2001.
89. Zeng, Q.Q., Jee, W.S., Bigornia, A.E., et al., “Time responses of cancellous and cortical bones to sciatic neurectomy in growing female rats,” Bone, 19, 13, 1996.
90. Orsatti, M.B., Fucci, L.L., Valenti, J.L., and Puche, R.C., “Effect of bicarbonate feeding on immobilization osteoporosis in the rat,” Calcif. Tissue Res., 21, 195, 1976.
91. Shaker, J.L., Fallon, M.D., Goldfarb, S., et al., “WR-2721 reduces bone loss after hindlimb tenotomy in rats,” J. Bone Miner. Res., 4, 885, 1989.
92. Uhthoff, H.K., Sekaly, G., and Jaworski, Z.F., “Effect of long-term nontraumatic immobilization on metaphyseal spongiosa in young adult and old beagle dogs,” Clin. Orthop., 192, 278, 1985.
93. Jee, W.S., Li, X.J., and Ke, H.Z., “Skeletal adaptations to mechanical usage in the rat,” Cell Mater., 1S, 131, 1991.
94. Klein, L., Player, J.S., Heiple, K.G., et al., “Isotopic evidence for resorption of soft tissues and bone in immobilized dogs,” J. Bone Joint Surg. Am., 64, 225, 1982.
95. Thomas, T., Skerry, T.M., Vico, L., et al., “Ineffectiveness of calcitonin on a local-disuse osteoporosis in the sheep: a histomorphometric study,” Calcif. Tissue Int., 57, 224, 1995.
96. Thomas, T., Vico, L., Skerry, T.M., et al., “Architectural modifications and cellular response during disuse-related bone loss in calcaneus of the sheep,” J. Appl. Physiol., 80, 198, 1996.
97. Grynpas, M.D., Kasra, M., Renlund, R., and Pritzker, K.P., “The effect of pamidronate in a new model of immobilization in the dog,” Bone, 17, 225S, 1995.
98. Ellsasser, J.C., Moyer, C.F., Lesker, P.A., and Simmons, D.J., “Effect of low doses of disodium ethane-1-hydroxy-1,1-diphosphonate on disuse osteoporosis in the denervated cat tail,” Clin. Orthop., 91, 235, 1973.
99. Kawano, S., Kanda, K., Ohmori, S., et al., “Effect of estrogen on the development of disuse atrophy of bone and muscle induced by tail-suspension in rats,” Environ. Med., 41, 89, 1997.
100. Chappard, D., Chennebault, A., Moreau, M., et al., “Texture analysis of X-ray radiographs is a more reliable descriptor of bone loss than mineral content in a rat model of localized disuse induced by the Clostridium botulinum toxin,” Bone, 28, 72, 2001.
101. Young, D.R. and Schneider, V.S., “Radiographic evidence of disuse osteoporosis in the monkey (M. nemestrina),” Calcif. Tissue Int., 33, 631, 1981.
102. Young, D.R., Niklowitz, W.J., Brown, R.J., and Jee, W.S., “Immobilization-associated osteoporosis in primates,” Bone, 7, 109, 1986.
103. Zorbas, Y.G., Naexu, K.A., and Federenko, Y.F., “Mechanisms of osteoporosis development during prolonged restriction of motor activity in dog,” Rev. Esp. Fisiol., 50, 47, 1994.
104. Little, D.G., Cornell, M.S., Briody, J., et al., “Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits,” J. Bone Joint Surg. Br., 83, 1069, 2001.
105. Kawata, T., Fujita, T., Tokimasa, C., et al., “Suspension ‘hypokinesia/hypodynamia’ may decrease bone mass by stimulating osteoclast production in ovariectomized mice,” J. Nutr. Sci. Vitaminol. (Tokyo), 44, 581, 1998.
106. Morey, E.R. and Baylink, D.J., “Inhibition of bone formation during spaceflight,” Science, 201, 1138, 1978.
107. Rantakokko, J., Uusitalo, H., Jamsa, T., et al., “Expression profiles of mRNAs for osteoblast and osteoclast proteins as indicators of bone loss in mouse immobilization osteopenia model,” J. Bone Miner. Res., 14, 1934, 1999.
108. Anderson, J.E., Lentz, D.L., and Johnson, R.B., “Recovery from disuse osteopenia coincident to restoration of muscle strength in mdx mice,” Bone, 14, 625, 1993.
109. Tuukkanen, J., Wallmark, B., and Jalovaara, P., “Changes induced in growing rat by immobilization and remobilization,” Bone, 12, 113, 1991.
110. Sievanen, H., Kannus, P., and Jarvinen, T.L., “Immobilization distorts allometry of rat femur: implications for disuse osteoporosis,” Calcif. Tissue Int., 60, 387, 1997.
111. Kannus, P., Järvinen, T.L.N., and Sievänen, H., “Effects of immobilization, three forms of remobilization and subsequent deconditioning on bone mineral content and density in rat femora,” J. Bone Miner. Res., 11, 1339, 1996.
112. Rubin, C., Xu, G., and Judex, S., “The anabolic activity of bone tissue, suppressed by disuse, is normalized by brief exposure to extremely low-magnitude mechanical stimuli,” FASEB J., 15, 2225, 2001.
113. Brighton, C.T., Tadduni, G.T., Goll, S.R., and Pollack, S.R., “Treatment of denervation/disuse osteoporosis in the rat with a capacitively coupled electrical signal: effects on bone formation and bone resorption,” J. Orthop. Res., 6, 676, 1988.
114. Muths, E. and Reichman, O.J., “Kangaroo rat bone compared to white rat bone after short-term disuse and exercise,” Comp. Biochem. Physiol. A Physiol., 114, 355, 1996.
115. Smith, R.L., Thomas, K.D., Schurman, D.J., et al., “Rabbit knee immobilization: bone remodeling precedes cartilage degradation,” J. Orthop. Res., 10, 88, 1992.
116. Lindgren, J.U., DeLuca, H.F., and Mazess, R.B., “Effects of 1,25(OH)2D3 on bone tissue in the rabbit: studies on fracture healing, disuse osteoporosis, and prednisone osteoporosis,” Calcif. Tissue Int., 36, 591, 1984.
117. Dhem, A., Ars-Piret, N., and Waterschoot, M.P., “The effects of nandrolone decanoate on rarefying bone tissue,” Curr. Med. Res. Opin., 6, 606, 1980.
118. Rubin, C., Turner, A.S., Bain, S., et al., “Anabolism - low mechanical signals strengthen long bones,” Nature (London), 412, 603, 2001.
119. Rubin, C., Sun, Y.Q., Hadjiargyrou, M., and McLeod, K., “Increased expression of matrix metalloproteinase-1 in osteocytes precedes bone resorption as stimulated by disuse: evidence for autoregulation of the cell’s mechanical environment?" J. Orthop. Res., 17, 354, 1999.
120. Gross, T.S., Akeno, N., Clemens, T.L., et al., “Selected Contribution: Osteocytes upregulate HIF-1alpha in response to acute disuse and oxygen deprivation,” J. Appl. Physiol., 90, 2514, 2001.
121. Milicic, M. and Jowsey, J., “Effect of fluoride on disuse osteoporosis in the cat,” J. Bone Joint Surg. Am., 50, 701, 1968.
122. Minne, H.W., Pfeilschifter, J., Scharla, S., et al., “Inflammation-mediated osteopenia in the rat: a new animal model for pathologic loss of bone mass,” Endocrinology, 115, 50, 1984.
123. Hoshino, K., Hanyu, T., Arai, K., and Takahashi, H.E., “Mineral density and histomorphometric assessment of bone changes in the proximal tibia early after induction of type II collagen-induced arthritis in growing and mature rats,” J. Bone Miner. Metab., 19, 76, 2001.
124. Enokida, M., Yamasaki, D., Okano, T., et al., “Bone mass changes of tibial and vertebral bones in young and adult rats with collagen-induced arthritis,” Bone, 28, 87, 2001.
125. Moran, E.L., Fornasier, T.L., and Bogoch, T.R., “Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts,” J. Orthop. Res., 18, 873, 2000.
126. Fountos, G., Kounadi, E., Tzaphlidou, M., et al., “The effects of inflammation-mediated osteoporosis (IMO) on the skeletal Ca/P ratio and on the structure of rabbit bone and skin collagen,” Appl. Radiat. Isot., 49, 657, 1998.
127. Bunger, C., Bunger, E.H., Harving, S., et al., “Growth disturbances in experimental juvenile arthritis of the dog knee,” Clin. Rheumatol., 3, 181, 1984.
128. Yoshitake, H., Rittling, S.R., Denhardt, D.T., and Noda, M., “Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption,” Proc. Natl. Acad. Sci. U.S.A., 6, 96, 8156, 1999.
129. Simonet, W.S., Lacey, D.L., Dunstan, C.R., et al., “Osteoprotegerin: a novel secreted protein involved in the regulation of bone density,” Cell, 89, 309, 1997.
130. Bucay, N., Sarosi, I., Dunstan, C.R., et al., “Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification,” Genes Dev., 12, 1260, 1998.
131. Mizuno, A., Amizuka, N., Irie, K., et al., “Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin,” Biochem. Biophys. Res. Commun., 247, 610, 1998.
132. Min, H., Morony, S., Sarosi, I., et al., “Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis,” J. Exp. Med., 192, 463, 2000.
133. Li, B., Boast, S., de los Santos, K., et al., “Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation,” Nat. Genet., 24, 304, 2000.
134. Xu, T., Bianco, P., Fisher, L.W., et al., “Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice,” Nat. Genet., 20, 78, 1998.
135. Delany, A.M., Amling, M., Priemel, M., et al., “Osteopenia and decreased bone formation in osteonectin-deficient mice,” J. Clin. Invest., 105, 915, 2000.
136. Ducy, P., Amling, M., Takeda, S., et al., “Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass,” Cell, 100, 197, 2000.
137. Ogata, N., Chikazu, D., Kubota, N., et al., “Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover,” J. Clin. Invest., 105, 935, 2000.
138. Kuro-o, M., Matsumura, Y., Aizawa, H., et al., “Mutation of the mouse klotho gene leads to a syndrome resembling ageing,” Nature (London), 390, 45, 1997.
139. Rosen, C.J., Beamer, W.G., and Donahue, L.R., “Defining the genetics of osteoporosis: using the mouse to understand man,” Osteoporos. Int., 12, 803, 2001.
140. Takeda, T., Hosokawa, M., and Higuchi, K., “Senescence-Accelerated Mouse (SAM): a novel murine model of accelerated senescence,” J. Am. Geriatr. Soc., 39, 911, 1991.
141. Matsushita, M., Tsuboyama, T., Kasai, R., et al., “Age-related changes in bone mass in the Senescence-Accelerated Mouse (SAM): SAM-R/3 and SAM-P/6 as new murine models for senile osteoporosis,” Am. J. Pathol., 125, 276, 1986.
142. Delmas, P.D., Vergnaud, P., Arlot, M.E., et al., “The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?" Bone, 16, 603, 1995.
143. Champ, J.E., Binkley, N., Havighurst, T., et al., “The effect of advancing age on bone mineral content of female rhesus monkeys,” Bone, 19, 485, 1996.
144. Black, A., Tilmont, E.M., Handy, A.M., et al., “A nonhuman primate model of age-related bone loss: a longitudinal study in male and premenopausal female rhesus monkeys,” Bone, 28, 295, 2001.
145. Kaymakci, B. and Wark, J.D., “Precise accurate mineral measurements of excised sheep bones using X-ray densitometry,” Bone Miner., 25, 231, 1994.
146. Cadossi, R. and Cane, V., “Pathways of transmission of ultrasound energy through the distal metaphysis of the second phalanx of pigs: an in vitro study,” Osteoporos. Int., 6, 196, 1996.
147. Kawagoe, K., Saito, M., Shibuya, T., et al., “Augmentation of cancellous screw fixation with hydroxyapatite composite resin (CAP) in vivo,” J. Biomed. Mater. Res., 53, 678, 2000.
148. Lippuner, K., Vogel, R., Tepic, S., et al., “Effect of animal species and age on plate-induced vascular damage in cortical bone,” Arch. Orthop. Trauma Surg., 111, 78, 1992.
149. Schnitzer, T., Bone, H.G., Crepaldi, G., et al., “Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group,” Aging (Milan), 12, 1, 2000.
150. Peter, C.P., Guy, J., Shea, M., et al., “Long-term safety of the aminobisphosphonate alendronate in adult dogs. I. General safety and biomechanical properties of bone,” J. Pharmacol. Exp. Ther., 276, 271, 1996.
151. Okazaki, A., Matsuzawa, T., Perkin, C.J., and Barker, M.H., “Intravenous single and repeated dose toxicity studies of cimadronate (YM175), a novel bisphosphonate, in beagle dogs,” Toxicol. Sci., 20, 27, 1995.
152. Pienkowski, D., Doers, T.M., Monier-Faugere, M.C., et al., “Calcitonin alters bone quality in beagle dogs,” J. Bone Miner. Res., 12, 1936, 1997.
153. Lafage, M.H., Balena, R., Battle, M.A., et al., “Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study,” J. Clin. Invest., 95, 2127, 1995.
154. Boivin, G., Deloffre, P., Perrat, B., et al., “Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration,” Bone Miner. Res., 11, 1302, 1996.